# **Special Issue**

## Rhinovirus Infections 2.0

### Message from the Guest Editor

Rhinoviruses are small nonenveloped RNA viruses belonging to the family Picornaviridae, and are recognized as the major cause of common colds and acute exacerbations of asthma and chronic obstructive pulmonary disorder (COPD) in humans. These viruses are extremely antigenically diverse in structure, with approximately 160 distinct serotypes/strains grouped into three types, A, B, and C, with further distinctions based on entry receptor requirements where three different cell-surface molecules have been described. Immunity to rhinoviruses is generally considered to be serotype-specific. Despite intensive studies since their discovery in the 1960s, no effective antiviral or vaccine has been invented to combat these ubiquitous pathogens. In this updated Special Issue of *Viruses*, we aim to gather research and review papers that contribute to an improved understanding of rhinovirus structure, classification, infections, epidemiology, and immunopathology, or that report the development of vaccines or antiviral agents. Studies that address rhinovirus infections epidemiology during the COVID-19 pandemic are particularly encouraged.

#### **Guest Editor**

Prof. Dr. Gary McLean

- 1. Molecular Immunology, School of Human Sciences, London Metropolitan University, London, UK
- 2. Faculty of Medicine, National Heart & Lung Institute, Imperial College London, London, UK

### Deadline for manuscript submissions

closed (30 September 2022)



# **Viruses**

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/108291

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





## Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

### Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

### **Editor-in-Chief**

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

#### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

### **Journal Rank:**

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

